BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 74,438 Shares of Zoetis Inc. $ZTS

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 14.1% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 452,054 shares of the company’s stock after selling 74,438 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.10% of Zoetis worth $70,501,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. grew its position in Zoetis by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock worth $6,842,222,000 after acquiring an additional 189,287 shares during the last quarter. Polen Capital Management LLC grew its position in Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares during the last quarter. Northern Trust Corp grew its position in Zoetis by 1.2% during the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after acquiring an additional 78,508 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Zoetis by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock worth $847,293,000 after acquiring an additional 109,791 shares during the last quarter. Finally, Brown Advisory Inc. grew its position in Zoetis by 7.6% during the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock worth $725,866,000 after acquiring an additional 312,746 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 13.6%

Shares of Zoetis stock opened at $124.70 on Wednesday. Zoetis Inc. has a one year low of $122.00 and a one year high of $181.85. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The stock’s 50-day moving average is $146.33 and its 200 day moving average is $153.24. The firm has a market cap of $55.27 billion, a price-to-earnings ratio of 21.46, a PEG ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the prior year, the company earned $1.58 EPS. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.6%. Zoetis’s dividend payout ratio is presently 34.42%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Piper Sandler upped their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Argus reiterated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Stifel Nicolaus set a $140.00 price target on Zoetis in a research report on Tuesday. Finally, Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $192.14.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.